Brief: MannKind Q2 Operating Income USD 5.299 Million

MannKind

06/08/2025 12:05

Overview

MannKind Q2 2025 rev grows 6% yr/yr, driven by higher royalties and Afrezza demand

Company reports net income of $0.7 mln, reversing a loss from prior year

Co submits sBLA for Afrezza in pediatric population, advancing pipeline trials

Outlook

Company expects MNKD-201 Phase 2 trial initiation by year-end 2025

MannKind anticipates MNKD-101 interim enrollment target by early 4Q 2025

Company awaits Afrezza pediatric sBLA review decision in early 4Q 2025

Result Drivers

ROYALTIES BOOST - Revenue growth driven by increased royalties from Tyvaso DPI

AFREZZA DEMAND - Higher demand and pricing for Afrezza contributed to revenue increase

COLLABORATION REVENUE DECLINE - Decrease in collaboration revenue due to one-time items

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
$668,000
Q2 Basic EPS
Q2 Operating Income
$5.30 mln
Q2 Pretax Profit
$940,000


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MannKind Corp is $9.00, about 55.7% above its August 5 closing price of $3.99

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nGNX5mCnsl

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)